World's First AI‑Designed Vaccine Tested in Humans For The First Time
The pEVAC-PS shot was safe in 39 adults and triggered modest immune responses, but researchers say it has not yet been shown to prevent infection.
- Researchers led by the University of Cambridge successfully tested an AI-designed vaccine, pEVAC-PS, in a first-in-human clinical trial, confirming it was safe and well tolerated in 39 healthy volunteers.
- Traditional vaccines are reactive and require constant updates as viruses evolve, explained Professor Jonathan Heeney; his team developed an AI-designed 'super-antigen' targeting shared sarbecovirus features to provide future-proof protection.
- The experimental vaccine was delivered via needle-free PharmaJet Tropis device and produced modest immune responses against Omicron and Delta, though researchers did not observe broad neutralizing activity across all strains.
- Professor Saul Faust from the University of Southampton concluded that this class of vaccines could save millions of lives and prevent future lockdowns, though pEVAC-PS remains an early-stage candidate.
- A larger Phase 2 trial involving around 200 people is planned to examine immune responses in more diverse populations, determining whether the platform can shift public health from reacting to preventing pandemics.
20 Articles
20 Articles
AI designed a specially modified superantigen.
Congo-Kinshasa: World's First AI-Designed Vaccine Explained
Analysis - Researchers at the University of Cambridge have developed what they describe as a fundamentally new type of vaccine using artificial intelligence (AI). The vaccine's key component was designed entirely by AI and has now been tested in people for the first time.
World’s first AI-designed vaccine explained
Sooksaard/Shutterstock.comResearchers at the University of Cambridge have developed what they describe as a fundamentally new type of vaccine using artificial intelligence (AI). The vaccine’s key component was designed entirely by AI and has now been tested in people for the first time. The goal is ambitious: a single vaccine that works not just against all known human coronavirus variants, but against related bat viruses that could jump from an…
Coverage Details
Bias Distribution
- 46% of the sources lean Left, 45% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
